Ruifu Chemical Supply Ivabradine Hydrochloride Intermediates With High Purity
Ivabradine Hydrochloride CAS 148849-67-6
4,5-Dimethoxy-1-Cyanobenzocyclobutane CAS 35202-54-1
(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride CAS 866783-13-3
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one CAS 73942-87-7
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one CAS 148870-57-9
3-(3-Chloropropyl)-7,8-dimethoxy-1H-3-benzazepin-2(3H)-one CAS 85175-59-3
| Chemical Name | (1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride |
| Synonyms | Ivabradine Hydrochloride Intermediate; (1S)-4,5-Dimethoxy-1-(Methylaminomethyl)-Benzocyclobutane HCl |
| CAS Number | 866783-13-3 |
| CAT Number | RF-PI1811 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C12H18ClNO2 |
| Molecular Weight | 243.73 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Powder |
| Identification | HPLC/UV Complies |
| Specific Rotation | +14.0° ~ +19.0° (1% CH3OH) |
| Loss on Drying | <0.50% (Dry it at 105℃ in vacuum till a constant weight) |
| Individual Impurity | <0.50% |
| Optical Isomers | <0.50% |
| Purity / Analysis Method | >99.5% (% area normalization, by HPLC) |
| Assay | 99.0%~100.5% (on dried basis, by Titration) |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Ivabradine Hydrochloride (CAS: 148849-67-6) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride (CAS: 866783-13-3) is an intermediate used in preparation of Ivabradine Hydrochloride (CAS: 148849-67-6) which is a selective bradycardic agent with direct effect on the pacemaker If current of the sinoatrial node. Ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease.